FSD Pharma (HUGE) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free HUGE Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | bizjournals.comMedicus Pharma eyes IPO with 'groundbreaking' SkinJect patch in the pipelineMay 2, 2024 | msn.comU.S. factory orders rise 1.6% M/M in March, meeting consensusApril 26, 2024 | msn.comMerck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly BeatApril 25, 2024 | finance.yahoo.comFSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM)April 17, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and ProductsApril 17, 2024 | finance.yahoo.comFSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and ProductsMarch 30, 2024 | techcrunch.comSam Bankman-Fried gets 25 years in prison for fraud and money laundering at FTX, ordered to pay $11B in forfeitureMarch 16, 2024 | finance.yahoo.comHUGE Apr 2024 2.000 putFebruary 28, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Announces Debt SettlementFebruary 26, 2024 | msn.comBiotech Company Develops Inebriation Remedy Beverage 'UNBUZZD'November 7, 2023 | finance.yahoo.comFSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One BasisSeptember 18, 2023 | finance.yahoo.comFSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well ToleratedAugust 15, 2023 | finance.yahoo.comFSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023August 3, 2023 | finance.yahoo.comInvestmentPitch Media Video Features FSD Pharma’s Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification DrinkJune 23, 2023 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Granting of Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology to Celly NutritionJune 20, 2023 | msn.comFSD Pharma Announces Agreement To Grant Exclusive Rights To Recreational Alcohol Misuse TechnologyJune 20, 2023 | finance.yahoo.comFSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse TechnologyMay 25, 2023 | finance.yahoo.comFSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of DirectorsMay 13, 2023 | finance.yahoo.comFSD Pharma Inc. (HUGE.CN)May 11, 2023 | finance.yahoo.comFSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza BokhariMay 10, 2023 | msn.comPromising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing CompletedMay 10, 2023 | finance.yahoo.comFSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second CohortApril 19, 2023 | benzinga.comDynamic Duo of Celsius Holdings Fame join FSD Pharma calling Medical Product under Development "Unique and Disruptive"April 12, 2023 | finance.yahoo.comFSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023April 12, 2023 | finance.yahoo.comIIROC Trading Halt - HUGEApril 12, 2023 | finance.yahoo.comIIROC Trade Resumption - HUGEFebruary 21, 2023 | finance.yahoo.comFSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 ForumFebruary 15, 2023 | finance.yahoo.comFSD Pharma Regains Compliance with NASDAQ Continued Listing RequirementsFebruary 7, 2023 | proactiveinvestors.comFSD Pharma receives regulatory clearance for proposed Phase 1 clinical trial of multiple sclerosis drug candidate Lucid-MSJanuary 17, 2023 | proactiveinvestors.comFSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MSJanuary 17, 2023 | finance.yahoo.comFSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigationJanuary 9, 2023 | msn.comTesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On MondayJanuary 9, 2023 | proactiveinvestors.comFSD Pharma incorporates new subsidiary to capitalize on drug development incentives in AustraliaJanuary 9, 2023 | financialpost.comFSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in AustraliaJanuary 6, 2023 | finance.yahoo.comFSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023September 6, 2022 | finance.yahoo.comFDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation SyndromeJune 1, 2022 | proactiveinvestors.comFSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearanceMay 6, 2022 | finance.yahoo.comFSD Pharma Announces Dismissal of Derivative ComplaintMay 2, 2022 | seekingalpha.comFSD Pharma engages Tekkfund to help with business development strategiesApril 21, 2022 | proactiveinvestors.com.auFSD Pharma adds two new faces to its advisory boardApril 21, 2022 | finance.yahoo.comFSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory BoardApril 8, 2022 | finance.yahoo.comFSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza BokhariMarch 15, 2022 | nz.finance.yahoo.comFSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLCFebruary 25, 2022 | theglobeandmail.comStocks in play: FSD Pharma IncJanuary 18, 2022 | nasdaq.comFSD Pharma Inc. Class B Subordinate Voting Shares (HUGE)January 6, 2022 | stockhouse.comVectoIQ Acquisition Corp. II VTIQJanuary 1, 2022 | stockhouse.comXpresSpa Group Inc. XSPAJanuary 1, 2022 | stockhouse.comPinterest Inc. Class A PINSJanuary 1, 2022 | stockhouse.comRoyal Mail Plc ADR ROYMYDecember 22, 2021 | stockhouse.comA “HUGE” Investment Opportunity in Neurodegenerative and Mental Health Treatments Get FSD Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now HUGE Media Mentions By Week HUGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUGE News Sentiment▼0.000.45▲Average Computer and Technology News Sentiment HUGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUGE Articles This Week▼10▲HUGE Articles Average Week Get FSD Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HOC News OEE News LTV News ISD News ROI News ALY News ART News INX News VQS News IQ News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CNSX:HUGE) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
